• Citer

Prognostic and predictive 18F-FDG PET/CT-based imaging biomarkers in metastatic colorectal cancer

par Woff, Erwin
Président du jury Devière, Jacques
Promoteur Flamen, Patrick
Co-Promoteur Hendlisz, Alain
Publication Non publié, 2020-07-14

Thèse de doctorat

• Accès en ligne
• Détails
• Contenu
• Statistiques

Résumé :

The aim of this thesis was to develop and validate prognostic and predictive biomarkers in order to better identify among patients with metastatic colorectal cancer those at high-risk of early death or progression. The interest in developing such biomarkers is that their subsequent use in clinical practice would avoid exposing a patient for months to the toxic side effects of ineffective and expensive treatments, and thus to limit the financial impact of these treatments on our healthcare systems.The projects carried out in the framework of this thesis have shown that:The biomarker WB-MATV (metabolically active tumor volume of the whole body) measured before the start of the last line treatment has a high prognostic value, higher than the general clinical parameters commonly used. This biomarker was then validated in first line treatment and was shown to have a high prognostic value, also higher than the general clinical parameters.The biomarker cfDNA (circulating DNA) also representing the tumor load was then investigated to assess its value added to the previously validated WB-MATV. We showed that the presence of high levels of cfDNA before starting the last-line treatment is significantly associated with poor prognosis and that these two biomarkers are prognostically complementary, each providing an added value.The biomarker of early metabolic response to last line treatment has a high negative predictive value (95%). This biomarker was then validated as a predictive biomarker independent of WB-MATV and clinical factors in first-line treatment setting.In conclusion, the results of this thesis strongly support the clinical use of these prognostic and predictive biomarkers in patients with metastatic colorectal cancer. Allowing a more accurate stratification of patients, the use of the combination of these biomarkers should become an essential tool to help oncologists in tailoring therapeutic strategies according to the patients’ individual risk.